Most approved Alzheimer’s therapies target amyloid plaques — either blocking their formation or clearing them from the brain. A team at Heidelberg University is now proposing a different point of intervention entirely.
According to the announcement, researchers led by neurobiologist Prof. Dr. Hilmar Bading, director of the Institute of Neurobiology at Heidelberg University’s Interdisciplinary Center for Neurosciences, have identified a toxic interaction between two proteins that acts as a trigger for nerve cell death in Alzheimer’s disease. Working alongside researchers from Shandong University in China, the team used a mouse model of Alzheimer’s to demonstrate that this molecular mechanism drives cognitive decline — and that it can be chemically disrupted.
The two proteins involved are the NMDA receptor and the TRPM4 ion channel. NMDA receptors, activated by the neurotransmitter glutamate, support neuron survival and cognitive function when operating within synapses. Outside synaptic junctions, however, TRPM4 binds to them and fundamentally alters their behavior. Together, the pair forms what the researchers call a “death complex” capable of damaging and killing nerve cells.
To break apart this complex, the team deployed a compound called FP802, a “TwinF Interface Inhibitor” previously developed by Prof. Bading’s group. The molecule targets the precise interface where TRPM4 and NMDA receptors connect, preventing the interaction from forming. In treated Alzheimer’s mice, the results were measurable across multiple dimensions: reduced synapse loss, less mitochondrial damage, preserved learning and memory function, and a significant drop in beta-amyloid accumulation — the same plaque buildup that conventional therapies aim to address directly.
“In Alzheimer’s mice treated with the molecule, disease progression was markedly slowed,” said Dr. Jing Yan, formerly of Prof. Bading’s team and now with FundaMental Pharma.
Prof. Bading draws a deliberate distinction between this strategy and existing approaches. “Instead of targeting the formation or removal of amyloid from the brain, we are blocking a downstream cellular mechanism, the NMDAR/TRPM4 complex, that can cause the death of nerve cells and — in a disease-promoting feedback loop — promotes the formation of amyloid deposits,” he states. The implication is that amyloid buildup observed in Alzheimer’s may partly be a consequence of the death complex’s activity, not only a cause of disease.
More Read
Earlier work from the same group found that FP802 also showed neuroprotective effects in models of amyotrophic lateral sclerosis, suggesting the NMDAR/TRPM4 interaction may be a shared mechanism across multiple neurodegenerative diseases.
Prof. Bading is explicit about where the research currently stands. “The previous results are quite promising in the preclinical context, but comprehensive pharmacological development” is still required before any clinical application, he cautions. The path from a mouse model result to a human therapy involves extensive safety and efficacy testing that the team has not yet completed.
Photo by Pixabay
This article is a curated summary based on third-party sources. Source: Read the original article
